ibrutinib,acalabrutinib,venetoclax
astrazeneca,abbvie,janssen,roche
['cll', ' ibru', 'acalabrutinib']
 1l i+v for cll #ash2022
2-3yr of rx, driven by bm mrd
n=120, 23% del17p/tp53
best bm umrd 72%
low + mrd at 1y --&gt; 63% umrd in yr2 (63%)
early umrd attainment a/w duration of mrd-
4ypfs 95% (91% in tp53abn). truly impressive!
durable remission to btki with pts w pd 
Doc from Melbourne, Australia. Treats patients with blood cancers and researches new therapies. Loves family, immersive theatre and running.